Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient

Phase 1 Trial of Oral Treatment for Metastatic CRPC Doses First Patient
A first patient has been dosed in a Phase 1 clinical trial investigating the small molecule inhibitor EPI-7386 as a treatment for metastatic castration-resistant prostate cancer (CRPC), its developer, ESSA Pharma, reported. Metastatic CRPC is prostate cancer that has metastasized, or spread to distant regions, and is resistant to traditional treatments that lower levels of androgen hormones, like testosterone. Recruitment for this open-label trial (NCT04421222) testing four doses of the oral candidate, is underway at three U.S. sites: the Hematology Oncology Associates of the Treasure Coast in Florida, the Comprehensive Cancer Center of NV Las Vegas in Nevada, and at Washington University School of Medicine in Missouri. Additional testing sites in Florida and British Columbia are expected to open soon. Information is available here. "The initiation of this study represents a significant milestone for ESSA as it brings us a step closer to offering a potentially meaningful new therapeutic option to prostate cancer patients," David Parkinson, MD, CEO of ESSA, said in a press release. Research indicates that prostate cancer requires the presence of androgens in order to grow. For this reason, lowering androgen levels through surgery or hormone therapy is a mainstay of its treatment. When patients become resistant to these therapies, however, those that block the androgen receptor (AR) take the center stage. Several androgen receptor inhibitors — Zytiga (abiraterone acetate), Xtandi (enzalutamide), Erleada (apalutamide) — are now approved to treat prostate cancer. Still, many patients will develop resistance to both androgen lowering therapies and those blocking androgen signaling. Resistance often develops because the AR protein acquires mutat
Subscribe or to access all post and page content.